Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (345)	9/14/2007 7:40:19 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

I hope AFFX gave them volume discounts. That has to be tens of millions of dollars worth of microarrays. ------------------ For giggles let's compare the stock charts of the two companies. AFFX is up a little over the past five years, GLGC is down a lot. ILMN is up 1000%. fwiw, here is an article about affx & ilmn Nature 444, 256-257 (16 November 2006) The chips are down Geneticists' desire to track the roots of complex diseases has shaken up the market for gene chips. Meredith Wadman reports on two firms jostling for position in a business potentially worth US$500 million. nature.com I haven't followed the affx/ilmn lawsuit. The most recent article I find is this one reuters.com